Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 8/20 | 0.42 |
| ▸ | DRD3 | P35462 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053056 | 0.92 | MAPT (0.41) | MAPTSMN1; SMN2DRD4DRD3DRD2 | |
| SCHEMBL15053233 | 0.92 | KMT2A (0.42) | RAB9ANPC1ALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL15053550 | 0.92 | RAB9A (0.42) | RAB9AHTTSTING1HTR1AHTR2A | |
| SCHEMBL15053823 | 0.92 | BRAF (0.46) | RAB9ANPC1SMN1; SMN2STING1CYP1A2 | |
| SCHEMBL15053079 | 0.92 | DRD2 (0.42) | RAB9ALMNANPC1MAPTSTING1 | |
| SCHEMBL3709385 | 0.92 | DRD4 (0.47) | RAB9ALMNANPC1ALDH1A1MAPT | |
| SCHEMBL15053500 | 0.90 | BRAF (0.49) | STING1HTR2AHTR7HTR6BRAF | |
| SCHEMBL15053397 | 0.90 | HTT (0.42) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL15052475 | 0.90 | HTR1A (0.40) | LMNADRD4DRD3DRD2CACNA1F | |
| SCHEMBL15053860 | 0.90 | SMN1; SMN2 (0.46) | RAB9ANPC1MAPTSMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | RAB9A 2322/4885LMNA 2436/4885NPC1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.